Floatz logo

prt3645

Malignant Mesothelioma

Prelude TherapeuticsPhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

28 Active assets in the Malignant Mesothelioma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Dr Jean Yannis PERENTES
Phase 2BB
Inno-206
Mayo Clinic
Phase 2BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 2BB
Sargramostim
Memorial Sloan Kettering Cancer Center
Phase 2BB
TAMOXIFEN
Ottawa Regional Cancer Centre
Phase 2B

View all 50 →

Same molecule, other indications

prt3645 is also rated in:

non-small cell lung carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
sarcomaDormant
CC
Indicative ·
42 / 100
View asset →
glioblastomaDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →